Agreement（以下简称"认购协议"），约定由 WuXi Lux Holding 认缴投资基金1,000 万欧元的 A 类份 额，对应已募集投资基金份额的 持有的2,000万欧元基金认缴份额。 1.07%。同日，WuXi Lux Holding与 WuXi PharmaTech Healthcare Fund I L.P.（以下简称"WuXi Fund I"）签署Transfer Agreement（下称"转让协议"），约定 WuXi Lux Holding 格隆汇12月18日丨药明康德(603259.SH)公布，2025年12月18日，本公司全资子公司 按照最近一期投资人账户净资产价值及未出资认缴金额的总和受让WuXi Fund I WuXi Lux Holding 与Jeito CapitalS.A.S.（以下简称"管理公司"或"Jeito Capital"）签署Subscription 转让协议与认购协议完成后，WuXi Lux Holding 将合计持有投资基金3,000万欧元的 A 类份额，约占已 募集投资基金份额的 3.22%。截至本公告日，WuXiLux Holding 尚未支付投资款，后续 ...

Group 1 - JPMorgan Chase & Co. increased its stake in WuXi AppTec (02359.HK) by acquiring 872,123 shares at an average price of HKD 106.3228 per share, totaling approximately HKD 92.73 million [1] - Following this acquisition, JPMorgan's total holdings in WuXi AppTec rose to 31,416,623 shares, increasing its ownership percentage from 5.98% to 6.15% [1]

Group 1 - JPMorgan Chase & Co. increased its stake in WuXi AppTec (02359.HK) by acquiring 871,000 shares at an average price of HKD 106.3228 per share, totaling approximately HKD 92.73 million [1] - Following the acquisition, JPMorgan's total holdings in WuXi AppTec rose to 31,416,623 shares, increasing its ownership percentage from 5.98% to 6.15% [1]

| 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 281.79 | 23856.40 | 84.66 | -6.55 | 机构专用 | 华泰证券股份有限 | | | | | | | 公司上海分公司 | | 221.44 | 18746.69 | 84.66 | -6.55 | 机构专用 | 华泰证券股份有限 | | | | | | | 公司上海分公司 | | 154.72 | 13098.96 | 84.66 | -6.55 | 机构专用 | 华泰证券股份有限 | | | | | | | 公司上海分公司 | | 80.11 | 6782.47 | 84.66 | -6.55 | 瑞银证券有限责任公司上海 | 华泰证券股份有限 | | | | | | 花园石桥路证券营业部 | 公司上海分公司 | | 20.89 | 1768.89 | 84.66 | -6.55 | 瑞银证券有限责任公司上 ...

香港联交所最新数据显示，12月11日，摩根大通增持药明康德（603259）(02359)87.2123万股，每股作 价106.3228港元，总金额约为9272.66万港元。增持后最新持股数目约为3141.66万股，持股比例为 6.15%。 ...

智通财经APP获悉，香港联交所最新数据显示，12月11日，摩根大通增持药明康德(02359)87.2123万 股，每股作价106.3228港元，总金额约为9272.66万港元。增持后最新持股数目约为3141.66万股，持股 比例为6.15%。 ...

12月17日，药明康德大宗交易成交764.87万股，成交额6.48亿元，占当日总成交额的19.31%，成交价 84.66元，较市场收盘价90.59元折价6.55%。 ...

Core Insights - The article highlights the launch of the Super CEO series by Zhito Finance for the ninth consecutive year, featuring various sub-lists that reflect the diverse driving forces behind China's economic growth, particularly in the healthcare sector [1] Industry Overview - The Chinese pharmaceutical manufacturing industry is experiencing a decline, with revenue of 1,227.52 billion yuan in the first half of 2025, down 1.2% year-on-year, and total profit of 176.69 billion yuan, down 2.8% year-on-year, indicating ongoing industry pressure and deepening segmentation [1] - Since 2025, numerous policies have been introduced to support high-quality development in innovative pharmaceuticals, including measures to enhance the clinical trial approval process and the introduction of a commercial insurance directory for innovative drugs [2] - The medical device export sector continues to grow, with a total import and export value of 41.09 billion USD in the first half of 2025, a 1.1% increase year-on-year, while imports decreased by 3.9%, indicating a shift towards domestic alternatives in high-end equipment [3] Investment Trends - The overseas business development (BD) orders for innovative pharmaceuticals have reached a record high, surpassing 60 billion USD, with significant transactions indicating a shift in China's role from a follower to a contributor in the global pharmaceutical landscape [4] - Capital preferences are improving, with the healthcare industry in China seeing a recovery in financing activities, particularly in medical devices and innovative pharmaceuticals, with significant investments in areas like cancer screening and AI healthcare [5] Future Outlook - The 15th Five-Year Plan emphasizes the importance of health in economic development, aiming to enhance public health and support the growth of innovative drugs and medical devices, which will shape the future of the healthcare industry in China [6] - The aging population, active policy support, and the internationalization of medical devices are driving demand and supply upgrades in the healthcare sector, presenting both opportunities and challenges for industry leaders [6] CEO Insights - The Super CEO list features 25 leaders whose companies have shown median revenue growth of 6.11% and net profit growth of 16.08%, with an average market capitalization of 86.1 billion yuan [9] - The list includes a notable representation of women leaders, with three female CEOs demonstrating strong strategic vision in high-barrier industries [10] - The majority of CEOs on the list have advanced degrees, reflecting the industry's demand for leaders with deep scientific understanding and business acumen [10] Company Highlights - Li Ge, CEO of WuXi AppTec, leads the list, showcasing strong performance with a revenue of 32.857 billion yuan in the first three quarters of 2025, a year-on-year increase of 18.61% [17] - Zhu Yi, CEO of BaiLi TianHeng, achieved significant revenue growth through strategic partnerships, emphasizing the importance of building a robust product pipeline [18] - Wu Hao, CEO of Mindray, reported a revenue of 36.726 billion yuan in 2024, with a focus on R&D and international expansion [19] - Zhong Huijuan, CEO of Hansoh Pharmaceutical, became the richest woman in China with a revenue of 12.261 billion yuan in 2024, driven by innovative drug sales [19] - Shi Yifeng, CEO of Aimeike, led the company to a revenue of 3.026 billion yuan in 2024, emphasizing shareholder value through high dividend payouts [20]

药明康德出售附属公司交割完成公告要点 交易完成情况： 财务影响： 相关方将办理股权变更登记手续 预计2025年12月31日前完成变更登记 各方仍需继续履行股权转让协议约定 重要提示： 股东及投资者买卖证券时需谨慎行事 上海药明已收到高瓴支付的第一期转让对价人民币15.4亿元 股权转让交割先决条件已满足，交易完成交割 康德弘翼及津石医药不再纳入公司合并报表范围 预计产生税后净利润约人民币9.6亿元 占公司2024年度经审计归母净利润比例超过10% 具体影响金额以注册会计师年度审计确认结果为准 后续安排： ...

Core Viewpoint - WuXi AppTec (603259) has completed the sale of all shares of Kande Hongyi and Jinshi Pharmaceutical to Hillhouse Capital, receiving an initial payment of RMB 1.54 billion, with the transaction expected to generate a post-tax net profit of approximately RMB 960 million, exceeding 10% of the company's audited net profit for the fiscal year 2024 [1][1][1] Group 1 - WuXi AppTec has received the first phase of the transfer price of RMB 1.54 billion from Hillhouse Capital as per the equity transfer agreement [1] - The transaction has met the conditions for delivery, and Kande Hongyi and Jinshi Pharmaceutical will no longer be included in the company's consolidated financial statements [1] - The equity change registration procedures for Kande Hongyi and Jinshi Pharmaceutical are expected to be completed by December 31, 2025 [1] Group 2 - The estimated post-tax net profit from this transaction is approximately RMB 960 million, which represents over 10% of the company's most recent audited net profit for the fiscal year 2024 [1] - The company will account for the investment income according to Chinese Accounting Standards and International Financial Reporting Standards, with the specific impact amount to be confirmed by the annual audit [1] - All parties involved are required to continue fulfilling the agreements stipulated in the equity transfer agreement [1]